Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.48 -1.70%

-$0.22 today

Market cap
$253.75M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.31M

Average 0.74M

Returns on capital

Q32 Bio Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

71.0%

avg -109.3%

ROIC

29.5%

avg -61.6%

ROA

48.3%

avg -41.4%

Analysis

ROE is currently the strongest return metric at 71.0% versus its period average of -109.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jodie Pope Morrison

Chief Executive Officer & DirectorUSD 1M50340.04K2.66%

Lee H. Kalowski

Chief Financial Officer & PresidentUSD 792.77K45——

Shelia Violette

Co-founder, Chief Scientific Officer & President of ResearchUSD 641.88K65——

José Trevejo

Chief Medical OfficerUSD 627.92K54——

Elham Hershberger

Chief Development Officer—58——

David Appugliese

Senior Vice President & Head of People————

Maria Marzilli

Chief Business Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

4

$30.00M

Sells

11

$505,079.50

Net Transaction Value

+$29.49M

Net buying

Most Active

Morrison Jodie Pope

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 6, 26

Morrison Jodie Pope

Direct

Sell$26.8K
Oct 6, 26

Kalowski Lee

Direct

Sell$10.8K
Oct 6, 26

Violette Shelia M.

Direct

Sell$7.6K
Aug 25, 26

Kalowski Lee

Direct

Sell$65.8K
Aug 25, 26

Violette Shelia M.

Direct

Sell$46.3K
Aug 25, 26

Morrison Jodie Pope

Direct

Sell$163K
May 28, 26

Xu Diyong

Indirect

Buy$10M
May 28, 26

Xu Diyong

Indirect

Buy$5M
May 28, 26

ORBIMED ADVISORS LLC

Indirect

Buy$10M
May 28, 26

ORBIMED ADVISORS LLC

Indirect

Buy$5M

1–10 of 15

Summary

Insiders reported 4 buys worth $30.00M and 11 sells worth $505,079.50 over the last 12 months. That adds up to net buying of $29.49M. Morrison Jodie Pope was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
-40.7% (5yr)2 analysts
RevenueN/AN/A+100.7%
+23.9% (5yr)2 analysts
Net IncomeN/AN/AN/A
-40.7% (5yr)2 analysts
EBITN/AN/AN/A
-27.0% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +100.7% over three years. Forward estimates point to Revenue at +23.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Q32 Bio Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about QTTB's management, answered from reported figures.

Who manages QTTB?

Q32 Bio Inc. (QTTB) lists 7 active executives. The top listed executive is Shelia Violette, Co-founder, Chief Scientific Officer & President of Research.

Are QTTB insiders buying or selling?

Recent insider activity shows net buying of $34.02M.